Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction

Arthritis and Rheumatism

Volumn 54, Issue 2, 2006, Pages 463-472

  Zwerina, Jochen ^a   Hayer, Silvia ^a   Redlich, Kurt ^a   Bobacz, Klaus ^a   Kollias, Giorgos ^b   Smolen, Josef S ^a   Schett, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 8677; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; RO 4399247; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; CARTILAGE DEGENERATION; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STEM CELL; SYNOVITIS; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CARTILAGE, ARTICULAR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32444438052     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21626     Document Type: Article

References (29)

1. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
2. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8.
3. StClair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
4. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
5. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
6. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 2002;65:44-8.
9. Chabaud-Riou M, Firestein GS. Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis. Am J Pathol 2004;164:177-84.
10. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
11. Revesz L, Blum E, di Padova FE, Buhl T, Feifel R, Gram H, et al. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg Med Chem Lett 2004;14:3595-9.
12. Geng Y, Valbracht J, Lotz M. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 1996;98:2425-30.
13. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999;1:94-7.
14. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002;143:3105-13.
15. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
16. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004;50:2327-37.
17. Palle S, Chappard D, Vico L, Riffat G, Alexandre C. Evaluation of the osteoclastic population in iliac crest biopsies from 36 normal subjects: a histoenzymologic and histomorphometric study. J Bone Miner Res 1989;4:501-6.
18. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
19. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
20. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-52.
21. Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 2001;187:294-303.
22. Nimah M, Zhao B, Denenberg AG, Bueno O, Molkentin J, Wong HR, et al. Contribution of MKP-1 regulation of p38 to endotoxin tolerance. Shock 2005;23:80-7.
23. Patten C, Bush K, Rioja I, Morgan R, Wooley P, Trill J, et al. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. Arthritis Rheum 2004;50:3334-45.
24. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291:680-7.
25. Neidhart M, Rethage J, Kuchen S, Kunzler P, Crowl RM, Billingham ME, et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic hypomethylation and influence on gene expression. Arthritis Rheum 2000;43:2634-47.
26. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, et al. Roles of tumor necrosis factor p55 and p75 receptors in TNF-α-induced vascular permeability. Am J Physiol Cell Physiol 2001;281:C1173-9.
27. Cara DC, Kaur J, Forster M, McCafferty DM, Kubes P. Role of p38 mitogen-activated protein kinase in chemokine-induced emigration and chemotaxis in vivo. J Immunol 2001;167:6552-8.
28. Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000;486:23-8.
29. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002;110:1419-27.